SpyGlass Pharma SGP

Patrick Mooney has served as our chief executive officer and a member of our board of directors since July 2021. Previously, from March 2017 to April 2021, Mr. Mooney served in various roles at Novartis, a pharmaceutical company, including vice president and head, Novartis Ophthalmic. Mr. Mooney also held various positions at Alcon, a pharmaceutical and medical device company, including leadership positions of increasing responsibility in sales, marketing and operations in the United States and Asia. Mr. Mooney holds a B.B.A. in marketing from the University of Wisconsin-Whitewater.

Malik Y. Kahook, M.D. co-founded SpyGlass and has served as our president and a member of our board of directors since January 2019, our chief medical officer since August 2024 and from January 2019 through November 2023, and our executive chair since January 2021. Since April 2012, Dr. Kahook has served as a professor and The Slater Family Endowed Chair in Ophthalmology at the University of Colorado Health, a healthcare system, and from June 2006 to April 2012, Dr. Kahook served as an associate professor at the University of Colorado Health. From October 2012 to November 2017, Dr. Kahook served as medical director of ClarVista Medical, an ophthalmology device company, that was acquired by Alcon in 2017. Dr. Kahook holds a B.S.N. from The University of Akron and an M.D., Medicine from the Northeast Ohio Medical University.

Chetan Pujara, Ph.D. has served as our Chief Research and Development Officer since February 2025 and previously provided consulting services to the Company from February 2024 to February 2025. From July 2023 to February 2025, Dr. Pujara served as Chief Development Officer at Osanni Bio, a biotechnology company. From May 2020 to July 2023, Dr. Pujara served in various roles at AbbVie, a biopharmaceutical company, including Vice President, Pharmaceutical Sciences, Research and Development (R&D). Prior to AbbVie, Dr. Pujara spent over 13 years in various R&D roles at Allergan, a pharmaceutical company. Dr. Pujara also spent 10 years in various roles at Abbott, a medical device and healthcare company. Dr. Pujara holds a B.Pharm from Birla Institute of Technology and Science, Pilani and a Ph.D. in Pharmaceutical Sciences from Purdue University.

Elizabeth O'Farrell has served as a member of our board of directors since August 2025. From April 1993 to December 2017, Ms. O'Farrell held various executive management positions at Eli Lilly and Company, a pharmaceutical company, including Chief Procurement Officer, Senior Vice President, Policy and Finance, and Chief Financial Officer, Lilly USA. Ms. O'Farrell also previously held roles at PricewaterhouseCoopers LLP and Whipple & Company Corporation. Ms. O'Farrell serves on the board of directors of Genmab A/S, PDL BioPharma, Geron Corporation, LENSAR, and previously served on the board of directors of Inhibikase Therapeutics from April 2019 to September 2022. Ms. O'Farrell holds a B.S.B. in accounting and an M.B.A. in management information systems each from Indiana University, Bloomington.

Bilal Khan has served as a member of our board of directors since September 2023. Since August 2008, Mr. Khan has served in various roles at New World Medical, an ophthalmic device manufacturing company, including Vice President, Chief Operating Officer, and President, and has served as Chief Executive Officer of New World Medical since October 2019. Mr. Khan holds a B.B.A. in Actuarial Science from the University of Wisconsin and an M.B.A. from The Wharton School of Business. Mr. Khan was formerly a Fellow of the Society of Actuaries.

Geoff Pardo has served as a member of our board of directors since May 2025. Since June 2011, Mr. Pardo has served as the President and General Partner of Gilde Healthcare US Inc., a healthcare investor. Mr. Pardo currently serves on the board of directors of Mainstay Medical Holding plc, Nalu Medical, Alleviant Medical, Shoulder Innovations, and Ablative Solutions. Previously, Mr. Pardo served on the board of directors of Inari Medical Inc. from March 2018 to May 2021, Axonics Inc. from July 2017 to April 2019, Eargo Inc. from July 2020 to July 2021, and CVRx Inc. from August 2016 to June 2022. Mr. Pardo received a B.A. in history from Brown University and an M.B.A from The Wharton School of Business.

Kirk Nielsen has served as a member of our board of directors since July 2025 and previously served as a member of our board of directors from December 2020 to July 2023. Mr. Nielsen has served as a Managing Partner at Vensana Capital, a medtech-focused investment firm, since January 2019 and as a Managing Director at Versant Ventures, a healthcare-focused venture capital firm, since January 2011. Mr. Nielsen currently serves on the board of directors of CVRx and several boards of directors for private companies, including Elucent Medical, iVEAcare, Moxe Health, Okami Medical, Rampart, and Vensana Innovation, and he previously served on the boards of directors for numerous other companies, including Alleviant Medical, Artelon, and Inari Medical. Mr. Nielsen holds an A.B. from Harvard College and an M.B.A. from Harvard Business School.

Glenn Sussman co-founded SpyGlass in January 2019 and served as our Chief Executive Officer through July 2021. He transitioned to our Chief Technology Officer in July 2021 and continued to serve in that role through December 2025. In January 2026, Mr. Sussman transitioned to serving as our Chief Technology Advisor and continues to serve in that role. From June 2018 to May 2019, Mr. Sussman served as an entrepreneur in residence at the University of Colorado, Department of Ophthalmology. From March 2013 to May 2018, Mr. Sussman served as Vice President, R&D at ClarVista Medical, an ophthalmology company. Mr. Sussman previously spent 18 years in a R&D leadership role at Alcon. Mr. Sussman holds a B.S. in mechanical engineering from California State University, Long Beach.

Michael Dybbs, Ph.D. has served as a member of our board of directors since November 2025. Dr. Dybbs is currently a Partner at Samsara BioCapital, an asset management firm focused on the life sciences industry, where he has worked since March 2017. Previously, Dr. Dybbs was a Partner at New Leaf Venture Partners, L.L.C., where he worked from May 2009 until September 2016. Before joining New Leaf Venture Partners, L.L.C., Dr. Dybbs was a Principal at the Boston Consulting Group. Dr. Dybbs currently serves on the board of directors of Nkarta, Inc., Sutro Biopharma, Inc. and Kalaris Therapeutics, Inc. and serves on the boards of directors of several privately held companies. Dr. Dybbs previously served on the boards of directors of Dimension Therapeutics, Inc., a publicly traded company acquired by Ultragenyx Pharmaceutical Inc. in 2017, and Versartis, Inc. Dr. Dybbs received an A.B. in biochemical sciences from Harvard College and a Ph.D. in molecular biology from the University of California, Berkeley, where he was awarded a Howard Hughes Medical Institute fellowship.

Zach Scheiner, Ph.D. has served as a member of our board of directors since July 2023. Dr. Scheiner joined RA Capital Management, L.P., an investment manager, in April 2015 as an associate, became an analyst in April 2017, a principal in December 2017, and has been a partner since December 2025. Prior to joining RA Capital, Dr. Scheiner was a Science Officer at the California Institute for Regenerative Medicine (CIRM), where he worked from September 2008 to March 2015. Dr. Scheiner currently serves on the board of directors of Nkarta Therapeutics, Inc., LENZ Therapeutics, Inc. and several private biotechnology companies. Dr. Scheiner holds a B.S. in molecular biophysics and biochemistry from Yale University and a Ph.D. in neurobiology and behavior from the University of Washington.

Jean-Frederic Viret, Ph.D. has served as our Chief Financial Officer since January 2026. From November 2023 to June 2025, Dr. Viret served as Chief Financial Officer of NGM Biopharmaceuticals, Inc., a biopharmaceutical company. From February 2023 to September 2023, Dr. Viret served as Chief Financial Officer of Shasqi, Inc., a biopharmaceutical company, and from March 2021 to November 2022, Dr. Viret served as Chief Financial Officer of Blade Therapeutics, Inc., a biotechnology company. From September 2014 to March 2021, Dr. Viret served as Chief Financial Officer of Coherus BioSciences, Inc. (now known as Coherus Oncology), a commercial-stage biopharmaceutical company. Earlier in his career, Dr. Viret was Chief Financial Officer at diaDexus, Inc., XDx, Inc. (now CareDx, Inc.) and Anesiva, Inc., and worked in a variety of finance roles at Tularik Inc. and PricewaterhouseCoopers. Dr. Viret served as Chief Financial Officer of diaDexus from February 2014 to September 2014. diaDexus filed a voluntary petition for relief under the provisions of Chapter 7 of Title 11 of the United States Code on June 13, 2016. Dr. Viret holds a B.S. in engineering from the Institut National Polytechnique de Lorraine, an M.B.A. from Cornell University, and a Ph.D. in plant molecular biology from Universite Louis Pasteur (Strasbourg I). Dr. Viret was a visiting fellow at Harvard University and a postdoctoral fellow at the Massachusetts Institute of Technology.

Ali Behbahani, M.D. has served as a member of our board of directors since May 2019. Dr. Behbahani joined New Enterprise Associates (NEA), a venture capital firm, in 2007 and is currently a Partner and the Co-Head of Healthcare. Prior to joining NEA, he worked as an intern and later as a consultant in business development at The Medicines Company, a specialty pharmaceutical company developing acute care cardiovascular products. He previously held positions as a Venture Associate at Morgan Stanley Venture Partners from 2000 to 2002 and as a Healthcare Investment Banking Analyst at Lehman Brothers from 1998 to 2000. Dr. Behbahani currently serves on the board of directors of Adaptimmune Therapeutics Plc, Black Diamond Therapeutics, CRISPR Therapeutics AG, Monte Rosa Therapeutics, Inc., Nkarta, Inc., Korro Bio, Inc., and Arcellx, Inc. Dr. Behbahani previously served as a member of the board of directors of CVRx, Inc. from July 2013 to September 2024, Genocea Biosciences from February 2018 to May 2022, Minerva Surgical, Inc. from May 2011 to January 2024, and Oyster Point Pharma from July 2017 to January 2023. Dr. Behbahani received a B.S.E. in biomedical engineering, electrical engineering and chemistry from Duke University, an M.B.A. from the Wharton School of the University of Pennsylvania and an M.D. from the University of Pennsylvania School of Medicine.

James Dennewill has served as our Chief Operating Officer since October 2021 and served as our General Manager from November 2019 to October 2021. Prior to SpyGlass, Mr. Dennewill held several leadership roles at Cianna Medical, a women's health company, including Director of Operations from November 2013 to December 2015, Vice President of Manufacturing from January 2016 to October 2016, and Vice President of Operations from October 2016 to October 2019, until the company's acquisition by Merit Medical. Mr. Dennewill holds a B.S. in Finance and Operations from California State University, Long Beach and an M.B.A. from Yale School of Management.

Habib Dable was appointed to the board of directors of SpyGlass Pharma, Inc. on February 5, 2026 in connection with the Company's initial public offering. Mr. Dable has served as an advisor at RA Capital Management, L.P., an investment manager, since April 2022. Previously, Mr. Dable served as President and Chief Executive Officer of Acceleron Pharma Inc., a biopharmaceutical company, from December 2016 until its acquisition by Merck in November 2021. Prior to joining Acceleron, Mr. Dable held roles of increasing responsibility at Bayer AG beginning in 1994, serving as the President of Pharmaceuticals for Bayer in the U.S. from October 2015 until December 2016. From 2013 to 2015, Mr. Dable served as the Executive Vice President and Global Head of Specialty Medicine for Bayer HealthCare Pharmaceuticals, and from 2010 to 2012, he was the Vice President of Ophthalmology & Global Launch Team Head for EYLEA. Mr. Dable currently serves as a member of the board of directors of Relay Therapeutics, Day One Biopharmaceuticals, and PepGen, and he previously served as a member of the board of directors of Millendo Therapeutics, Inc. from September 2018 until January 2021, Blueprint Medicines Corporation from June 2022 to July 2025, Aerovate Therapeutics from July 2023 to April 2025, and Albireo Pharma from August 2022 to March 2023. Mr. Dable holds a bachelor's degree in business administration and an M.B.A, each from the University of New Brunswick in Canada.